Gevo raises $107 million in its IPO as synbio stays in the spotlight

Earlier this week, isobutanol producer Gevo raised $107 million in its initial public offering (IPO). The synthetic biology company sold approximately 7.1 million shares at $15 apiece, with shares trading as high as $16.50 shortly afterwards. When Gevo first filed its S-1 in August, we were skeptica...

This research is archived and therefore no longer available. For further assistance please contact your Customer Success Manager or email ClientEngagementTeam@luxresearchinc.com. Thank you!

Related Research

Cargill follows ADM, invests in Seventure Partners' fund for the microbiome

News Commentary | November 25, 2020

This comes only a few weeks after ADM announced its investment in Seventure's Health for Life Capital II fund. Outside of Cargill and ADM, other strategic investors are serving as limited partners as well, including Danone, Novartis, and Lesaffre. For Cargill, this builds on the formation of its ... Not part of subscription

Ginkgo Bioworks to go public via $17.5 billion SPAC deal

News Commentary | May 13, 2021

Backed by Harry Sloan and Jeff Sagansky, this merger with Soaring Eagle Acquisition will give Ginkgo a pre‑money equity valuation of $15 billion, with an additional $2.5 billion for the combined entity – one of the biggest SPAC deals in recent times. This news comes on the heels of Zymergen's IPO ... To read more, click here.

Amyris partners with Ingredion to bring its Reb M sweetener to B2B market

News Commentary | May 13, 2021

With an estimated transaction value of $100 million, Ingredion will get exclusive license to sell and market Amyris' Reb M sweetener technology under this agreement. Additionally, Ingredion will also get a minority stake in Amyris' new production facility in Brazil, to be completed by Q4 2021. ... Not part of subscription